v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows used in operating activities:    
Net loss $ (130,196) $ (111,736)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 24,809 21,259
Depreciation expense 174 417
Accretion of investment discounts, net (2,937) (4,469)
Charge for in-process research and development ("IPR&D") milestones 4,000  
Other non-cash items 75 264
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (4,041) 3,635
Operating lease right-of-use assets 932 1,435
Deposits and other assets (2) 24
Accounts payable 1,284 305
Accrued expenses 4,936 (5,389)
Operating lease liabilities (1,014) (1,185)
Net cash used in operating activities (101,980) (95,440)
Cash flows used in investing activities:    
Purchases of property and equipment (55) (52)
Milestone payments related to IPR&D (4,000)  
Purchases of marketable securities (603,985) (201,377)
Proceeds from maturities of marketable securities 168,840 186,000
Net cash used in investing activities (439,200) (15,429)
Cash flows provided by financing activities:    
Proceeds from financings, net of issuance costs 544,614 256,688
Proceeds from exercise of stock options and RSUs vesting 20,837 3,701
Withholding taxes paid on stock-based awards (10,597) (3,152)
Net cash provided by financing activities 554,854 257,237
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents (218) 956
Net decrease in cash, cash equivalents and restricted cash equivalents 13,456 147,324
Cash, cash equivalents and restricted cash equivalents, beginning of period 227,636 78,837
Cash, cash equivalents and restricted cash equivalents, end of period 241,092 226,161
Reconciliation of cash, cash equivalents and restricted cash equivalents:    
Cash and cash equivalents 240,095 225,178
Restricted cash equivalents 997 983
Total cash, cash equivalents and restricted cash equivalents: $ 241,092 $ 226,161